Cover Image
市場調查報告書

乾眼症症候群的全球市場:2015∼2019年

Global Dry Eye Syndrome Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 338504
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
乾眼症症候群的全球市場:2015∼2019年 Global Dry Eye Syndrome Market 2015-2019
出版日期: 2015年08月26日 內容資訊: 英文 70 Pages
簡介

乾眼症症候群,由於眼淚的分泌數量的不足和淚液的汽化等使眼乾燥。伴隨疼痛和充血、燃燒般的疼痛、眼睛疲勞等。雖不能治癒但可控制症狀。使用眼科用藥和抗發炎劑等。預計全球乾眼症症候群市場以2014∼2019年的年複合成長率4.75%擴大。

本報告提供全球乾眼症症候群市場現狀及未來方案的相關調查、市場規模、收益預測、各地區趨勢,及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

  • 市場概要
  • 主要供應商的產品

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • 乾眼症症候群的理解
  • 種類
  • 風險因素
  • 症狀
  • 原因
  • 流行病學
  • 診斷
  • 管理

第6章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 開發平台分析

  • Cyclokat
  • Diquas
  • EBI-005
  • MIM-D3
  • Lifitegrast
  • RGN-259
  • EBI-005
  • EGP-437

第8章 乾眼症的各子類型市場區隔

第9章 各藥物市場區隔

  • 口服抗生劑
  • 眼科用藥
  • 插入材
  • 軟膏

第10章 各地區市場區隔

第11章 推動市場要素的影響

第12章 市場課題

第13章 促進要素與課題的影響

第14章 市場趨勢

第15章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2014年
  • 其他值得注意的供應商

第16章 主要供應商分析

  • Alcon
  • Allergan
  • 大塚集團株式會社
  • Santen Pharmaceuticals

第17章 附錄

第18章 Technavio的檢驗

圖表

目錄
Product Code: IRTNTR6905

About dry eye syndrome

Dry eye syndrome usually results in dryness of eyes due to deficient tear production or quick tear evaporation or deviation in tear uniformity. This syndrome is of two types: aqueous tear deficient dry eye and evaporative dry eye. In aqueous tear deficient dry eye, lacrimal glands do not produce enough tears, whereas meibomian gland dysfunction results in evaporative dry eye. Meibomian glands secrete lipids to slow tear evaporation and maintain tear stability. The symptoms include pain, redness, burning, and fatigue in the eye and decreased tolerance to continuous visual activity. Dry eye syndrome cannot be cured, but symptoms can be controlled. Teardrops and anti-inflammatory drugs are used in the treatment.

Technavio's analysts forecast the global dry eye syndrome market to grow at a CAGR of 4.75% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global dry eye syndrome market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of teardrops and anti-inflammatory drugs used in the treatment of dry eye syndrome.

Technavio's report, Global Dry Eye Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Alcon
  • Allergan
  • Otsuka Holdings
  • Santen Pharmaceuticals

Other Prominent Vendors

  • Acadia Pharmaceuticals
  • Aciex
  • Allostera Pharma
  • arGentis
  • Auven Therapeutics (Celtic)
  • Bridge Pharma
  • Can-Fite
  • Cellzome

Key market driver

  • Growing prevalence of dry eye syndrome
  • For a full, detailed list, view our report

Key market challenge

  • Self-medication by patients
  • For a full, detailed list, view our report

Key market trend

  • Growing awareness about the syndrome
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding dry eye syndrome
  • Types of dry eye syndrome
  • Risk factors for dry eye syndrome
  • Signs and symptoms
  • Causes of dry eye syndrome
  • Epidemiology
  • Diagnosis
  • Disease management

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Pipeline analysis

  • Cyclokat
  • Diquas
  • EBI-005
  • MIM-D3
  • Lifitegrast
  • RGN-259
  • EBI-005
  • EGP-437

PART 08: Market segmentation by sub-type of dry eye

PART 09: Market segmentation by drug type

  • Oral antibiotics
  • Eye drops
  • Eye inserts
  • Eye ointments

PART 10: Geographical segmentation

  • Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 16: Key vendor analysis

  • Alcon
  • Allergan
  • Otsuka Holdings
  • Santen Pharmaceuticals

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Regional prevalence of dry eye syndrome
  • Exhibit 03: Diagnosis of dry eye syndrome
  • Exhibit 04: Surgical options
  • Exhibit 05: Punctal plugs
  • Exhibit 06: Global dry eye syndrome market 2014-2019 ($ billions)
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Market segmentation by sub-type of dry eye
  • Exhibit 09: Dry eye syndrome: pharmacologic therapy
  • Exhibit 10: Artificial tears: Different generations
  • Exhibit 11: Global dry eye syndrome market share 2014
  • Exhibit 12: Global dry eye syndrome: Key drivers
  • Exhibit 13: Impact of drivers
  • Exhibit 14: Global dry eye syndrome: Key challenges
  • Exhibit 15: Impact of drivers and challenges
  • Exhibit 16: Global dry eye syndrome: Emerging trends
  • Exhibit 17: Global dry eye syndrome market share analysis 2014
  • Exhibit 18: Alcon: Business strategy
  • Exhibit 19: Alcon: Distribution of sales by category 2014
  • Exhibit 20: Alcon: Region-wise sales distribution 2014 ($ millions)
  • Exhibit 21: Alcon: Region-wise sales distribution 2013 ($ millions)
  • Exhibit 22: Systane: Global sales 2011-2014 ($ millions)
  • Exhibit 23: Allergan: Business strategy
  • Exhibit 24: Eye care pharmaceuticals: Global sales 2011-2014 ($ millions)
  • Exhibit 25: Restasis: Global sales 2011-2014 ($ millions)
  • Exhibit 26: Santen Pharmaceuticals: Business strategy
  • Exhibit 27: Hyalein: Global sales 2011-2014 ($ millions)
  • Exhibit 28: Diquas: Global sales 2011-2014 ($ millions)
  • Exhibit 29: Prescription ophthalmics : Global sales 2011-2014 ($ millions)
  • Exhibit 30: Alcon: Business segmentation 2014
  • Exhibit 31: Allergan: Business segmentation by revenue 2014
  • Exhibit 32: Allergan: Business segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 33: Allergan: Geographical segmentation by revenue 2014
  • Exhibit 34: Santen Pharmaceutical: Business/Product segmentation 2014 by revenue
Back to Top